A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma

Basal cell carcinoma (BCC) is the most common malignancy in fair-skinned populations. Most cases are successfully treated with surgery, but advanced BCC—including locally BCC and metastatic BCC—surgery likely to result substantial morbidity or unlikely be effective. In those patients, systemic Hedgehog inhibitors (HHIs) sonidegib vismodegib only approved pharmacologic treatment option. Although a number of clinical studies highlight similarities differences between two HHIs, no head-to-head comparison available. Results from pivotal BOLT ERIVANCE for vismodegib, respectively, demonstrate similar efficacy measured by objective response rate, complete histologic tumor subtype. Safety results both comparable adverse events reported muscle spasms, alopecia, dysgeusia. A notable difference their respective pharmacokinetic profiles reaching peak concentration plasma within 2–4 hours dosing steady state achieved week 17 treatment, while reaches approximately 2 days after single dose 21 repeated dosing. This review compares efficacy, safety, pharmacokinetics based on published literature date. J Drugs Dermatol. 20(2):156-165. doi:10.36849/JDD.2021.5657THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE. PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT THIS WITHOUT LOGGING IN. NO PURCHASE NECESSARY. CONTACT PUBLISHER WITH ANY QUESTIONS.